SEC Form 4/A · accession 0001451612-26-000022

Kymera Therapeutics, Inc. · KYMR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Bruce Booth

Director

Period of report

Jun 26, 2026

Accepted (ET)

Jul 2, 2026 · 5:39 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001815442

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2,F3,F4	Jun 29, 2026	S	5,549	$105.78	D	2,446,375	I	See footnote
Common Stock^F2,F5,F4	Jun 29, 2026	S	14,798	$106.63	D	2,431,577	I	See footnote
Common Stock^F2,F6,F4	Jun 29, 2026	S	19,419	$107.76	D	2,412,158	I	See footnote
Common Stock^F2,F7,F4	Jun 29, 2026	S	10,848	$108.28	D	2,401,310	I	See footnote
Common Stock^F2,F8,F4	Jun 29, 2026	S	7,968	$109.75	D	2,393,342	I	See footnote
Common Stock^F2,F9,F4	Jun 29, 2026	S	7,723	$110.67	D	2,385,619	I	See footnote
Common Stock^F2,F10,F4	Jun 29, 2026	S	934	$111.20	D	2,384,685	I	See footnote
Common Stock^F2,F3,F11	Jun 29, 2026	S	770	$105.78	D	471,497	I	See footnote
Common Stock^F2,F5,F11	Jun 29, 2026	S	2,133	$106.63	D	469,364	I	See footnote
Common Stock^F2,F6,F11	Jun 29, 2026	S	2,698	$107.76	D	466,666	I	See footnote
Common Stock^F2,F7,F11	Jun 29, 2026	S	1,498	$108.28	D	465,168	I	See footnote
Common Stock^F2,F8,F11	Jun 29, 2026	S	1,104	$109.75	D	464,064	I	See footnote
Common Stock^F2,F9,F11	Jun 29, 2026	S	1,078	$110.67	D	462,986	I	See footnote
Common Stock^F2,F10,F11	Jun 29, 2026	S	130	$111.20	D	462,856	I	See footnote

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
F10The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive.
F11The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
F2The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10).
F4These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive.
F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive.
F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive.

Remarks

This Amendment is being filed to address an inadvertent clerical error in the original Form 4 relating to the allocation of the reported sales between Atlas Venture Fund X and AVOF. The aggregate number of shares sold by Atlas Venture Fund X and AVOF, as reported in the original Form 4, remains unchanged.